against pathogens and tumors. However, the rules that govern which peptides are truly
recognized by existing T cell receptors (TCRs) remain poorly understood, precluding
accurate predictions of neo-epitopes for cancer immunotherapy. Here, we capitalize on
recent (neo-) epitope data to train a predictor of immunogenic epitopes (PRIME), which
captures molecular properties of both antigen presentation and TCR recognition. PRIME not …